2022
Tanzania HIV Investment Case (IC) 2.0: Using modeling to explore optimization under severe resource constraints
Hiebert L, Resch S, Schutte C, Turay M, Zekeng L, Matiku S, Semini I, Stover J, Forsythe S, Hecht R. Tanzania HIV Investment Case (IC) 2.0: Using modeling to explore optimization under severe resource constraints. Journal Of Global Health Reports 2022, 5 DOI: 10.29392/001c.30063.Peer-Reviewed Original Research
2012
Vaccine research and development
Hecht R, Jamison D, Augenstein J, Partridge G, Thorien K. Vaccine research and development. 2012, 299-334. DOI: 10.1017/cbo9781139236805.009.Peer-Reviewed Original ResearchAIDS vaccineInternational AIDS Vaccine InitiativeAnti-retroviral therapyImmune deficiency syndromeAIDS vaccine developmentTime AIDSHIV infectionDeficiency syndromeVaccine researchNew infectionsVaccine InitiativeVaccine developmentTreatment programInfectious diseasesVaccineInfectionPercent efficacyAIDSPreventionEpidemicTreatmentYearsPercentUniversal accessHIV
2011
Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries
Resch S, Korenromp E, Stover J, Blakley M, Krubiner C, Thorien K, Hecht R, Atun R. Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries. PLOS ONE 2011, 6: e25310. PMID: 21998648, PMCID: PMC3187775, DOI: 10.1371/journal.pone.0025310.Peer-Reviewed Original ResearchConceptsMiddle-income countriesAIDS treatmentProgram costsIncome countriesLarge health gainsAntiretroviral therapyHIV infectionOpportunistic infectionsGlobal FundLife careMedical treatmentAIDS diseaseTreatment programHealth gainsCurrent cohortTotal program costsTreatmentPatientsCohortInfectionCareEnd 2011Same periodEconomic benefitsLabor productivity effects